- Home
- MDGL vs SRAD Comparison
MDGL vs SRAD Comparison
Compare MDGL & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- SRAD
- Stock Information
- Founded
- MDGL 2011
- SRAD 2001
- Country
- MDGL United States
- SRAD Switzerland
- Employees
- MDGL N/A
- SRAD N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- SRAD Computer Software: Programming Data Processing
- Sector
- MDGL Health Care
- SRAD Technology
- Exchange
- MDGL Nasdaq
- SRAD Nasdaq
- Market Cap
- MDGL 6.8B
- SRAD 6.8B
- IPO Year
- MDGL N/A
- SRAD 2021
- Fundamental
- Price
- MDGL $275.26
- SRAD $23.91
- Analyst Decision
- MDGL Strong Buy
- SRAD Strong Buy
- Analyst Count
- MDGL 10
- SRAD 13
- Target Price
- MDGL $420.63
- SRAD $26.23
- AVG Volume (30 Days)
- MDGL 335.5K
- SRAD 1.8M
- Earning Date
- MDGL 05-01-2025
- SRAD 05-12-2025
- Dividend Yield
- MDGL N/A
- SRAD N/A
- EPS Growth
- MDGL N/A
- SRAD 114.88
- EPS
- MDGL N/A
- SRAD 0.20
- Revenue
- MDGL $317,383,000.00
- SRAD $1,245,020,536.00
- Revenue This Year
- MDGL $285.43
- SRAD $18.84
- Revenue Next Year
- MDGL $63.77
- SRAD $15.21
- P/E Ratio
- MDGL N/A
- SRAD $119.95
- Revenue Growth
- MDGL N/A
- SRAD 23.07
- 52 Week Low
- MDGL $200.63
- SRAD $9.95
- 52 Week High
- MDGL $377.46
- SRAD $25.85
- Technical
- Relative Strength Index (RSI)
- MDGL 38.56
- SRAD 56.34
- Support Level
- MDGL $265.39
- SRAD $23.29
- Resistance Level
- MDGL $275.54
- SRAD $24.50
- Average True Range (ATR)
- MDGL 11.39
- SRAD 0.81
- MACD
- MDGL -1.08
- SRAD -0.00
- Stochastic Oscillator
- MDGL 24.12
- SRAD 71.53
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.